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Introduction
Bisphosphonates (BPs) represent a class of drugs that
are applied in therapy of different pathological conditions
related to bone. Their main role in bone metabolism is to in-
hibit osteoclast function, so these drugs act as potent devices
in suppression of the bone resorption process. Considering
the presence of two phosphonate groups with a high affinity
for calcium ions in their chemical structure, BPs have the
ability to accumulate predominantly in bones 
1. According to
the differences in side chain, related to the presence or ab-
sence of nitrogen atom, BPs are classified in two different
groups: nitrogen containing (aminoBPs) and non-nitrogen
containing (non-aminoBPs) drugs. These two groups of
bisphosphonates also differ in mechanism by which they in-
hibit osteoclast action. Aminobisphosphonates (pammidro-
nate, neridronate, olpadronate, ibandronate, risedronate,
zoledonate) act directly on HMG-CoA reductase (mevalo-
nate) pathway by binding and blocking enzyme farnesil di-
phosphate synthetase (FPPS) 
2. Non-amino bisphosphonates
(etidronate, clodronate, tiludronate) are metabolised within
osteoclasts to analogues of adenosine triphosphate (ATP)
that accumulate within the cells, which leads to inhibition of
numerous metabolic enzymes, cytotoxicity and apoptosis 
3–6.
Nitrogen addition greatly increases the potency of bisphos-
phonate, so aminoBPs are claimed to be 10–10,000 times
more potent comparing non-aminoBPs 
7.
As they act as inhibitors of osteoclast function in order
to suppress bone resorption and improve bone mineral den-
sity, during the past three decades, bisphosphonates have
been increasingly used in therapy of diferrent pathologic
conditions related to bone. Intravenous BPs are principally
used for treatment of metastatic bone lesions, multiple mye-
loma and hypercalcemia of malignancy. Oral BPs take part
in therapy of osteoporosis, Paget disease and paediatric os-
teogenesis imperfecta. Positive effects of bisphosphonates in
these conditions are: significant reduction of bone pain, os-
teolytic lesions and fracture risk, and improvement of bone
mineral density.
BPs are considered as drugs of certified efficiency,
with rare negative side effects, such as gastrointestinal in-
tolerance, headache, hypocalcemia, hypophosphatemia,
bone pain, dizziness, fever, fatigue etc. 
8, probably due to
their low serum concentration and rapid accumulation in
bone matrix.
History and definition of bisphosphonate-related
osteonecrosis of the jaw
In 2003 Marx 
9 described non-healing and painful ex-
posure of jaw bone after intravenous administration of potent
aminobisphosphonates in patients with multiple myeloma
and metastatic bone lesions, and soon, this adverse effect
was named bisphosphonate-related osteonecrosis of the jaw
(BRONJ).
BRONJ in a short time became the main and most
speculated adverse effect of BPs therapy 
10. In 2009 the
American Association of Oral and Maxillofacial Surgeons
(AAOMS) defined criteria for BRONJ: the presence of ex-
posed necrotic bone in maxillofacial region for more than 8Volumen 71, Broj 8 VOJNOSANITETSKI PREGLED Strana 773
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weeks in patients that currently take, or used to take
bisphosphonates, with no history of radiation therapy to the
jaws 
11. AAOMS also proposed staging system for BRONJ
according to symptoms, clinical and radiographic findings,
and recommended treatment strategy for each stage (Table
1)
11. Risk factors included in developing BRONJ are
pointed out in many studies on this subject 
3, 11–14. Now it is
known that BRONJ mostly occur in patients who used to
receive more potent, nitrogen containing BPs, in the treat-
ment of multiple myeloma or metastatic bone lesions.
Long-term therapy and intravenous administration of BPs
are associated with increased risk for developing BRONJ.
Local risk factors include oral-surgery interventions, such
as tooth extraction, implant placement etc., but also chronic
irritations (inadequate dentures), and chronic periodontal
disease. In the majority of reported cases, local trauma,
particularly tooth extraction, appear to be the direct cause,
in fact, the trigger factor in developing BRONJ, yet there
are reported cases that occur spontaneously, with no previ-
ous dental treatement, or trauma 
12, 15. Futhermore, there are
also areas within the jaws, that show greater predilection to
this complication. Lesions are found more commonly in the
mandible than in the maxilla (ratio 2 : 1), and more often in
areas where thin oral mucosa overlies bony prominences
and ridges 
11, 15.
Incidence of bisphosphonate-related osteonecrosis of
the jaw
According to the current literrature review 
16 the inci-
dence of BRONJ associated with parenteral administration,
showed a high variation from 0.00% to 27.5%, mean value
7% (in studies reported from 2003 to March 2010), but these
reviewed studies showed also high variance in duration and
design (retrospective, prospective, letters to editor and re-
view).
The overall incidence of BRONJ associated with oral
bisphosphonate therapy was estimated to be 0.12%, ranging
from 0.00% to 4.3%, also with variations in study type and
its duration
 16.
The importance of investigation of biphosphonate
therapy
While the clinical presentation of BRONJ is well-
known and described, the exact etiology and pathogenesis
still remains an enigma, despite a number of suggested theo-
ries that tried to give an appropriate explanation. Besides, the
question that has not been completely answered yet is: Why
are the jaws almost the only affected area? There were rare
reports in the literature of bisphosphonate-related osteone-
crosis affecting other bones 
17–21, so jaws remain, certainly
the main target for this complication of BPs therapy.
Cognition of the exact etiology and pathogenesis of this
adverse effect may make it be predictable, help its prevention
and facilitate its treatment, which is often without an ade-
quate response.
Etiopathogenesis
While there is more or less concordance among reports
in clinical presentation and risk factors related to BRONJ, a
concrete etiology and pathogenesis are still confusing and
therefore, there is a tendency in the literature to give an ap-
propriate explanation for this adverse effect of bisphospho-
nate therapy.
Suggested hypotheses are related to bone turnover sup-
pression, angiogenesis suppression, soft tissue toxicity, in-
fection and local pH value changes, immune system defi-
ciency, and genetic predisposition 
22–26.
Via osteoclast inhibition (what is actually their
mechanism of action), BPs definitely, on many levels, dis-
turb communication and signaling pathways among cells
included in bone remodelling, which leads to supression of
this process or at least to its defective enactment. As jaws
have a high remodelling rate, they would be the most af-
fected area 
27. Whereas the osteoclasts are, undoubtly, the
main target cells for BPs, there are also speculations and
studies about BPs’ effect on other bone cells: osteocytes
and osteoblasts, which affection could play a role in patho-
genesis of BRONJ, too.
Table 1
Bisphosphonate-related necrosis of the jaw (BRONJ) risk staging
BRONJ stages Clinical features Treatment strategy
Patients at risk No apparent necrotic bone in asymptomatic patients treated
with IV or oral bisphosphonate.
Patients should be informed on the risks of de-
veloping BRONJ.
Stage 0 No clinical evidence of necrotic bone, but the presence of non-
specific symptoms or clinical and radiographic findings that
address osteonecrosis.
Symptomatic treatment and conservative man-
agement of local factors, such as caries and
periodontal disease.
Stage I Exposed and necrotic bone in asymptomatic patients with no
evidence of infection.
Antimicrobial rinses, such as chlorhexidine
0.12%.
Stage II Exposed and necrotic bone in patients with pain and clinical
evidence of infection.
Antimicrobial rinses in combination with anti-
biotic therapy.
Stage III Exposed and necrotic bone in patients with pain, infection and
one or more of the following: exposed necrotic bone extending
beyond the region of alveolar bone; pathologic fracture; extra-
oral fistula; oral antral/ oral nasal communication; osteolysis
extending to the inferior border of the mandible or sinus floor.
Surgical debridement, including resection in
combination with antibiotic therapy.Strana 774 VOJNOSANITETSKI PREGLED Volumen 71, Broj 8
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BPs cause acumullation of avital bone matrix with non-
viable osteocytes, which has been already proved on animal
model 
28, but it has not been clarified yet whether it is a con-
sequence of their indirect action, through remodelling su-
pression, or direct effect on osteocytes’ viability, when these
cells are exposed to high concentrations of BPs.
In in vitro studies of BPs’ action, the direct effect of
BPs on cells of the osteoblast lineage is confirmed and ap-
peared to be dose-dependent, so it seems that BPs may in-
hibit bone formation process, too 
29, 30.
Subramanian et al. 
31 actually believe that combined re-
duction in bone formation and bone resorption leads to sig-
nifficant attenuation of bone remodelling response to
physiological stimuli such as bone aging, microdamage and
mechanical stress, so bone matrix with apoptotic osteocytes
persists unresorbed and unrepaired. Finally, BRONJ devel-
ops when local remodelling aparature is not able anymore to
maintain homeostasis and respond to bone damage subse-
quent to dentoalveolar infection, local trauma, or , the most
frequent, tooth extraction.
The effect of BPs treatement on vasculature has been
speculated in some studies
 22, 23. It is familiar that BPs act as
potent devices in suppression of angiogenesis associated
with tumor growth, and their antiangiogenic effect has been
documented. Exposed bone subsequent to BPs therapy does
not bleed and it is visiably avascular. However, more potent
substances with antiangiogenic action, that are in clinical
use, do not lead to osteonecrosis of the jaw, except reported
cases of treatement with bevacizumb- monoclonal human
antibody that through inhibition of vacular endothelial
growth factor A (VEGF-A) achieves antiangiogenic potential
32. Since these reports are extremly rare, we cannot make a
conclusion of antiangiogenic effect of BPs as the main causal
factor included in etiopathogenesis of BRONJ. In 2010, Yin,
Bai and Luo 
22 established a hypothesis of addititious, indi-
rect antiangiogenic effect of BPs, via inhibition of osteo-
clasts, that impact this process, and further suppression of
angiogenesis as in the study of Cackowski et al. 
33.
Furhermore, it has been suggested that BPs accumu-
lated in bone after tooth extraction play with direct toxic ef-
fect on oral epithelium, keratinocytes and fibroblasts, com-
promiting soft tissue healing, so the exposed bone becomes
necrotic
25, 34, 35. Otherwise, reported cases of BRONJ that
develops without prior invasive intervention, such as tooth
extraction, confront this theory. Besides, an open question is
whether or not oral mucosa is exposed to enough concentra-
tions of BPs, which are known to accumulate, predomi-
nantly, in bone?
Otto et al. 
24, 35 hypothesized that local infection and sub-
sequent changes of local pH value have important role in
pathogenesis of BRONJ. AminoBPs are known to bind to
bone matrix in neutral pH, but their relase and activation take
place in acid environment, which starts cascade of pathways
and leads to BRONJ. Since jaws, especially mandible, are
acessible to infecton, despite other area of the skeleton, this
theory could give an atrractive explanation of the pact that os-
teonecrotic process predominanatly affects jaws. This patho-
physiological mechanism has been proved in vitro, on cellular
level, where it has been adjusted that nitrogen containing BPs
act as more toxic in acid environment, in contrast to non-
nitrogen containing BPs 
36. Having in mind this study, the fact
that BRONJ mostly occures in cases with iv administration of
aminobisphosphonates, might not be surprising. Recent studies
pointed at Atctinomyces colonisation associated with
BRONJ 
37 and one metagenomic study revealed Proteobacte-
ria, Furmicutes and Actinobacteria being the domminant
phylotypes in BRONJ patients, but also detected associated vi-
ruses 
38.
It is still unclear, yet, whether extraction or infection is
the real trigger for BRONJ development. This theory, how-
ever, related to pH value changes, explains why preventive
measures before and during BPs therapy are very important
and successful, which has been proved in some studies 
39, 40.
Tooth extraction is always associated with loss of integrity of
the soft and hard intraoral tissue. This procedure enables di-
rect invasion of intraoral microorganisms into extraction
socket. Because of abundance of microorganisms in the oral
cavity, also regarding the previous fact, it is difficult to con-
sider extraction without infection.
None of these theories could give a complete, con-
spicuous explanation for etiopathogenesis of BRONJ. It
seems that all these theories are complementary to each
other, and the majority of promoted mechanichms could be
included in this process, although none of them has been ex-
perimentally confirmed.
A relatively new bone antiresorptive agent, denosumab,
that is approved by the Food and Drug Administration for
use in patients with osteoporosis and metastatic bone disease,
has been associaeted wit osteonecrosis of the jaw, too. Nev-
ertheless, according to its different pharmacology character-
isics and more rapidly reversible impact on bone turnover
comparing to bisphosphonates, as it was explained in a study
by Malan et al. 
41, osteonecrosis of the jaw related to deno-
sumab might resolve in a shorter drug holiday period.
Treatement strategy and outcome
The treatment strategy for managing BRONJ depends
on the stage of this condition (Table 1) and consists of pre-
ventive measures, antibiotic medication, surgical debride-
ment/resection and sometimes even discontinuation or modi-
fication of bisphosphonate therapy. The last mentioned
should be done only if systemic conditions permit and in ob-
ligate consultation with the treating physician or oncologist
and patient about risks and benefits of continuing bisphos-
phonate therapy
 42.
There is an agreement among all experts about treat-
ment difficulties concerning BRONJ, because of frequent
relapse after conservative or surgical therapy. Doubtless, im-
plementation of adequate prevention measures in patients
treated with bisphosphonates are very important and require
a multidisciplinary approach.
Clinical manifestation of BRONJ could be very similar
to many pathological conditions of maxillofacial region.
Considering differential diagnosis, it is very important for
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BPs administration, malignancy or osteoporosis). Clinic have
to distinguish BRONJ from other lesions in maxillofacial re-
gion (oral carcinoma, cysts, chronic irritation of oral mucosa,
alveolitis after tooth extraction, malignant ameloblastoma)
because the treatment strategies of these pathologies are
completely different 
43, 44.
Conclusion
It could be concluded that BRONJ is a serious negative
side effect of bisphosphonate therapy, that impacts nega-
tively on patients’ quality of life since it is painful, nonheal-
ing and often without adequate response to the applied ther-
apy, especially when it has not been recognised on time.
BRONJ certainly requires attention and further investigation.
Effective treatment could be achieved only if ethiopatho-
genesis was clarified.
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